CLINICAL PHENOTYPES AND MORTALITY RATES OF ALCOHOLIC LIVER CIRRHOSIS IN PATIENTS WITH PREVIOUS COVID-19 INFECTION
##semicolon##
alcoholic liver cirrhosis,##common.commaListSeparator## COVID-19,##common.commaListSeparator## clinical phenotype,##common.commaListSeparator## mortality,##common.commaListSeparator## decompensation.Abstrak
Clinical phenotypes and mortality rates of alcoholic liver cirrhosis in patients with previous COVID-19 infection. This study investigated the clinical phenotypes and mortality outcomes in patients with alcoholic liver cirrhosis (ALC) and a history of COVID-19 infection. A retrospective-prospective observational study was conducted between 2022 and 2024 at the Bukhara Regional Clinical Hospital. A total of 120 patients were analyzed: 68 with prior COVID-19 infection and 52 as controls. The findings revealed that ALC patients with COVID-19 had higher rates of Child-Pugh C (46% vs. 25%, p=0.02), higher MELD scores (19.3 ± 5.2 vs. 15.1 ± 4.7, p=0.01), and increased mortality (35.3% vs. 17.3%, p=0.03). These results suggest that COVID-19 aggravates the clinical course of alcoholic liver cirrhosis, leading to more severe phenotypes and higher mortality.
##submission.citations##
1. Marjot T, Webb GJ, Barritt AS et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348-364.
2. Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650-2666.
3. WHO. Clinical management of COVID-19: interim guidance. World Health Organization. 2020.
4. European Association for the Study of the Liver (EASL). Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181.
5. Yilmaz N, Yonal O, Kurt R. Impact of COVID-19 infection on liver disease patients. Turk J Gastroenterol. 2021;32(6):501-509.
6. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171.
7. Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol. 2016;13(3):131-149.
8. Kim D, Li AA, Perumpail RB et al. Changing trends in etiology-based annual mortality from chronic liver disease in the United States. Hepatology. 2019;69(3):1064-1074.
9. Abdullaeva M.A., Shodmonov U.Sh. Jigar kasalliklarida klinik ko‘rsatkichlarning tahlili. Tibbiyotda yangi kun. 2022; 2(38): 45–50.
10. Karimova D.I., Xolmatova S.A. COVID-19 infeksiyasining surunkali jigar kasalliklari bilan bog‘liqligi. O‘zbekiston Tibbiyot Jurnali. 2021; (4): 62–66.
11. Ismoilov A.B., Alimov N.T. Alkogolli jigar kasalliklarining klinik xususiyatlari. Gastroenterologiya va gepatologiya axborotnomasi. Toshkent, 2020; (3): 15–20.
12. Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377:756–768.
13. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–1047.
14. Wong F, Piano S, Singh V, et al. Clinical features and evolution of COVID-19 in patients with cirrhosis: a multicenter study. J Hepatol. 2021;75(3):520–529.
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of decompensated cirrhosis. J Hepatol. 2018;69(2):406–460.
